Comparison of the Effectiveness of USG-Guided Interscalene Block Versus Combined Interscalen-Suprascapular Block for Arthroscopic Shoulder Surgery (ISB vs SSB)

February 25, 2026 updated by: Asuman Ocaklar

Comparison of the Effectiveness of Ultrasound-Guided Interscalene Block Versus Combined Interscalene and Suprascapular Nerve Blocks in Arthroscopic Shoulder Surgery

This study aims to compare two commonly used regional anesthesia techniques for shoulder arthroscopy: the ultrasound-guided interscalene block and the combined interscalene-suprascapular nerve block. Both techniques are routinely performed to reduce pain during and after shoulder surgery. The purpose of this study is to determine which method provides better postoperative pain control, reduces the need for pain medication, and causes fewer side effects such as diaphragmatic dysfunction. Participants will receive one of the two nerve block techniques before surgery, and their pain scores, opioid consumption, and respiratory effects will be monitored during the first 24 hours after the operation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Arthroscopic shoulder surgery is a commonly performed procedure, and effective perioperative analgesia is essential for improving patient comfort, reducing opioid consumption, and enabling early rehabilitation. The ultrasound-guided interscalene block is considered the standard regional anesthesia technique for shoulder surgery; however, it may cause hemidiaphragmatic paresis due to phrenic nerve involvement. To reduce this risk while maintaining effective analgesia, the combination of interscalene and suprascapular nerve blocks has recently gained attention as a promising alternative.

The suprascapular nerve supplies approximately 70% of sensory innervation to the shoulder joint, and its blockade may enhance postoperative pain control when combined with a low-volume interscalene block. This combined technique has been proposed as a potentially safer option with fewer respiratory side effects, particularly in patients at risk of reduced pulmonary reserve.

This prospective, randomized clinical study aims to compare the analgesic efficacy and respiratory effects of the ultrasound-guided interscalene block versus the combined interscalene-suprascapular nerve block in patients undergoing arthroscopic shoulder surgery. Participants will be assigned to one of the two block techniques prior to surgery. Standardized anesthesia and postoperative care protocols will be applied. Primary outcomes include postoperative pain scores and opioid consumption during the first 24 hours. Secondary outcomes include diaphragm excursion measurements, block-related complications, patient satisfaction, and recovery profiles.

The results of this study are expected to contribute to determining whether the combined technique provides comparable or superior analgesia with fewer respiratory side effects, potentially offering a safer alternative to traditional interscalene block for shoulder surgery.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Planned arthroscopic shoulder surgery ASA physical status I-III Age between 18 and 75 years Ability to provide informed consent Suitable for regional anesthesia with ultrasound guidance

Exclusion Criteria:

Allergy or contraindication to local anesthetics Coagulopathy or current anticoagulant therapy Infection at the block injection site Severe pulmonary disease (e.g., severe COPD) Pre-existing neurological deficit in the operative upper limb Body mass index > 40 kg/m² Pregnancy or breastfeeding History of phrenic nerve palsy Inability to cooperate with block procedure or follow-up

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Interscalene Block (ISB)
Participants in this arm will receive an ultrasound-guided interscalene brachial plexus block. The block will be performed at the level of the C5-C6 nerve roots using a high-frequency linear ultrasound probe. A local anesthetic solution will be injected around the brachial plexus under real-time ultrasound visualization. This intervention represents the standard regional anesthesia technique used for arthroscopic shoulder surgery.
Procedure: Ultrasound-Guided Interscalene Block
An ultrasound-guided interscalene brachial plexus block performed at the C5-C6 level using a high-frequency linear ultrasound probe. Local anesthetic is injected around the brachial plexus under real-time ultrasound visualization. This technique represents the standard regional anesthesia method for arthroscopic shoulder surgery.
Experimental: ISB+ Suprascapular Block ( ISB+ SSNB)
Participants in this arm will receive a combined regional anesthesia technique consisting of an ultrasound-guided interscalene block followed by an ultrasound-guided suprascapular nerve block. The interscalene block will be performed at the C5-C6 level using a high-frequency linear probe. The suprascapular nerve block will be administered at the suprascapular notch under ultrasound visualization. Local anesthetic will be injected around both the brachial plexus and the suprascapular nerve. This combined technique is intended to enhance postoperative analgesia while potentially reducing phrenic nerve involvement compared with the interscalene block alone
Procedure: Combined Ultrasound-Guided Interscalene and Suprascapular Nerve Blocks
A combined regional anesthesia technique consisting of an ultrasound-guided interscalene block performed at the C5-C6 level, followed by an ultrasound-guided suprascapular nerve block administered at the suprascapular notch. Local anesthetic is injected around both the brachial plexus and the suprascapular nerve under ultrasound guidance. This technique aims to improve postoperative analgesia while potentially reducing phrenic nerve involvement.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Postoperative Pain Score (VAS 0-24 Hours)
Time Frame: 0-24 hours after surgery
Postoperative pain intensity will be assessed using a standard 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores will be recorded at predefined postoperative time points (e.g., 1, 2, 6, 12, and 24 hours). The primary outcome will be the comparison of cumulative VAS scores between the interscalene block group and the combined interscalene-suprascapular block group during the first 24 postoperative hours.
0-24 hours after surgery

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Total Postoperative Opioid Consumption (0-24 Hours)
Time Frame: 0-24 hours after surgery
Total postoperative opioid consumption will be recorded during the first 24 hours after surgery. All opioid medications will be converted to intravenous morphine milligram equivalents (MME) for standardized comparison between groups. The cumulative opioid requirement of the interscalene block group will be compared with that of the combined interscalene-suprascapular block group.
0-24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Asuman Ocaklar

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 25, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 25, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 3, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HRÜ/26.01.72

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Pain

Clinical Trials on Ultrasound-Guided Interscalene Block

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings